Dynamic assessment of the tear film muco-aqueous and lipid layers using a novel tear film imager (TFI) by Segev, Fani et al.
Dynamic assessment of the tear film muco-aqueous and lipid layers using a novel 
tear film imager (TFI) 
Fani Segev 1, 2, Noa Geffen 1, 2, Anat Galor 3, 4, Yoel Cohen 5, Raanan Gefen 5, Avner 
Belkin 1, Yoel Arieli 5, 6, Shlomi Epshtein 5, Anat Oren 2, Alon Harris 7 
1. Ophthalmology, Meir Medical Center, Kfar Sava, Israel.
2. Department of Ophthalmology - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
3. Ophthalmology, Miami VA Medical Center, Miami, Florida, USA agalor@med.miami.edu.
4. Bascom Palmer Eye Institute, University of Miami, Miami, Florida, USA.
5. R&D department, AdOM Advanced Optical Technologies, Lod, Israel.
6. Department of Applied Physics, The Jerusalem College of Technology, Jerusalem, Israel.
7. Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ABSTRACT 
Purpose The objective of the study was to assess a new technology, the tear film imager (TFI), 
which can dynamically image the muco-aqueous and lipid layers. 
Methods Prospective pilot case series of individuals with and without dry eye (DE). Two 
sequential images were obtained with the TFI. Measurements were assessed for reproducibility 
and compared with clinically derived DE metrics. Individuals were grouped into DE categories 
based on signs of DE. 
Results 49 patients participated in the study with a mean age of 58.8 years (SD 15.9) and a 
female majority (69%). Reproducibility of the muco-aqueous layer thickness (MALT) was excellent 
(r=0.88). MALT measurements significantly correlated with the Schirmer score (r=0.31). Lipid 
break up time (LBUT) as measured by the TFI significantly correlated with the clinical measure of 
tear break up time (TBUT) (r=0.73). MALT and LBUT were significantly thinner and shorter, 
respectively, in the DE groups (mild–moderate and severe) compared with the control group. 
When comparing TFI parameters to clinically assessed signs, sensitivity of the device was 87% 
and specificity was 88%. 
Conclusion The TFI is the first machine capable of reproducibly measuring muco-aqueous 
thickness in human subjects which correlates with Schirmer score. In parallel, it assesses other 
important aspects of tear film function which correlate with clinician assessed DE metrics. 
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INTRODUCTION 
Dry eye (DE) is a common condition that includes a wide range of symptoms (vision and 
pain related) and signs (evaporative and aqueous deficiency).1 These clinical features 
are driven by a multitude of pathophysiological mechanisms (eg, inflammation, 
hyperosmolarity, nerve dysfunction, meibomian gland disease) that lead to a lack of tear 
homeostasis.2 DE symptoms are a source of morbidity, affecting both physical and mental 
functioning.3 
Given the many components of DE, different tests have been developed to assess 
various components of the tear film. Clinical tests are the ones most frequently used and 
indirectly measure different components of the lacrimal functional unit. For example, tear 
break up time (TBUT) indirectly measures evaporation and the Schirmer’s test indirectly 
measures tear production.4 These metrics are enhanced by a variety of imaging 
techniques that capture one or more components of the lacrimal functional unit. For 
example, LipiView (TearScience, Morrisville, North Carolina, USA) can quantify lipid 
thickness and provide images of meibomian glands5; Keratograph 5M (OCULUS, 
Arlington, Washington, USA) can quantify TBUT and tear meniscus height and provide 
images of meibomian glands6 and high-resolution anterior segment optical coherence 
tomography (HR-OCT) machines can provide cross-sectional images of the precorneal 
tear film, inferior tear meniscus tear and meibomian glands.7–9 Limitations with current 
technologies include quantifying tear parameters in a static manner, as is the case for 
tear meniscus height, and not having enough resolution to capture muco-aqueous 
thickness information. This reality makes the assessment of DE cumbersome as the 
physician must employ several clinical and diagnostic tests to evaluate the tear film. 
In the last few years, several attempts have been made to apply spectral interference 
methods to non-invasively study the thickness of the human tear film.10 This was 
demonstrated in vivo in humans with and without a contact lens.10 11 This technology was 
also applied to study the thinning rate of the tear film with and without emulsion eye-
drops.12 However, there is currently no commercially available device that uses spectral 
interference to measure tear film parameters. 
 
 
Recently, a device was developed by AdOM (Israel) that can directly and dynamically 
measure several aspects of tear physiology with one measurement. The tear film imager 
(TFI) uses spectral interference technology to image the corneal surface with a large field 
of view (6 mm diameter) and high lateral resolution. The TFI can measure muco-aqueous 
layer thickness (MALT)13 and lipid layer thickness (LLT) and assess for change over time. 
We herein report the initial results of the TFI device study. The primary goal of this pilot 
study was to assess safety and measurement reproducibility of the instrument. A 
secondary goal was to compare clinically assessed DE metrics with machine-assessed 
metrics. 
METHODS 
The study was conducted at the Meir Medical Center in Kfar Saba, Israel. The study was 
conducted in accordance to the principles of the Declaration of Helsinki. The novel TFI 
technology used was also approved by the Ministry of Health of Israel. 
TFI device 
The TFI is an optical device that illuminates broadband light at wavelengths that range 
from 450 to 1050 nm from a small halogen light source. The illumination optics project 
light towards the corneal front surface at broad angles of −50 to 50 degrees, while 
ensuring that light level is within the safety limits. The use of very wide angles ensures 
that the generated image will have large field of view. In contrast, OCT devices use a 
narrowband at the infrared wavelength and their axial resolution (A-scan resolution) 
depends on a narrowband interference measurement. As such, while both OCT and TFI 
technologies use reflected light interference patterns, the hyperspectral TFI analyses 
wideband reflectance (600 nm band), while the OCT analyses narrowband reflectance 
(tens of nanometres with the swept source OCT at most). This fundamental difference 
allows the TFI to reach single nanometre resolution when assessing the tear film 
sublayers, while the OCT can at most reach 2–3 μm resolution, more than three orders 
of magnitude apart. 
A small custom objective, positioned in the centre of the illumination lens, collects the 
reflected specular light from the curved corneal surface and creates a flat conjugate 
 
 
image at the camera and spectrometer locations. This image is used for capturing and 
analysing eye movements, blinks and for supporting the auto focus real time operations. 
The colour information in each pixel of the image is used to determine the interference of 
light resulting from the impact of the illuminated light with the thin layers of the tear film. 
Detailed spectrum data is used to analyse the tear film structure at the cornea centre, by 
comparing the collected spectral data to the anticipated reflectance spectra. The result of 
this fit yields thickness values for the muco-aqueous and lipid layers several times in each 
second. Typically, 10–15 values are collected per second during a measurement period 
of 40 s. 
The frequent measurements of the MALT and LLT construct a time series for each layer 
thickness parameter. The TFI algorithm calculates a representative value for each layer 
thickness parameter from the quasi-stable period after the blink relaxation and before the 
next blink. In addition, the TFI can recognise from the lipid layer time series a momentary 
drop of thickness which defines the ‘lipid break up’, and this information is used to derive 
the lipid break up time (LBUT) from last blink. 
DEVICE’S BASIC PERFORMANCE 
Prior to the study, the device performance and calibration were tested on a mock tear film 
(glass lens with an artificial two layer tear film). This mock tear film has a similar optical 
structure to the tear film and cornea surface. The stability (or variability) of the thickness 
measurements over the tear film mock was found to be at the subnanometre level for 
both lipid and muco-aqueous mock layers. The absolute measurements of the tear film 
mock layer thickness by the TFI matched the independent measurements performed 
using Ellipsometry methods in an independent laboratory. The TFI device design and 
implementation addresses the anticipated measurement differences between a mock tear 
film and a real tear film on top of a human eye, such as: 
1. The human eye has saccadic motions including micro-saccadic motions, blinks 
including partial blinks and other phenomena that interfere with fluent 
measurements. Capturing and analysing these eye behaviours are critical to 
determine the true tear film dynamics. The TFI detects these phenomena and 
takes them under consideration during the measurement process. 
 
 
2. With each blink, the tear film is reset with subsequent rearrangement of the tear 
film parameters. Moreover, even between blinks, the tear film layer structure 
changes due to evaporation, draining and other processes, which are important to 
concomitantly assess. The TFI non-contact measurement allows (and even 
requires) regular blinking to preserve the tear film dynamics. In addition, in order 
to capture the tear film dynamics between blinks, the TFI measures each layer 
thickness with nanometre accuracy, 10–15 times/s, which allows for a 
reconstruction of the tear film layer thickness dynamics of both the muco-aqueous 
and lipid layers. 
STUDY DESIGN 
Prospective, pilot study. We aimed to enrol 50 individuals into the study based on our 
primary outcome of assessing MALT reproducibility. Fifty individuals give us 81% power 
to detect a 15% difference between the measurements. This number of subjects also 
gives us 90% power to detect a 15% difference between our secondary analysis, a 
comparison of LBUT to TBUT. 
RECRUITMENT 
All patients seen in Meir Medical Center ophthalmic outpatient clinic who met criteria were 
offered recruitment into the study. As this was a pilot study, we included all comers and 
did not age and gender match as the goal was to evaluate the safety and reproducibility 
of the TFI. 
Inclusion criteria 
Patients with otherwise healthy external ocular anatomy. This included a mix of subjects 
with and without DE symptoms and signs. 
Exclusion criteria 
Patients were excluded if they had chronic ocular surface disease other than idiopathic 
DE (eg, Stevens-Johnson syndrome, post-burn ocular injury, herpes simplex virus 
infection, neurotrophic cornea), had any corneal disease (eg, scarring, oedema), used 
contact lenses, had an active intraocular inflammation or infection, used eye-drops (with 
 
 
the exception of artificial tears) or had intraocular surgery or surgical occlusion of the 
lacrimal puncta within 3 months. Subjects were asked not to use any topical eye drops 
on the day of their study visit. 
ASSESSMENTS 
DEMOGRAPHIC INFORMATION WAS OBTAINED. 
DE ASSESSMENT 
DE symptoms were assessed using the Ocular Surface Disease Index (OSDI).14 DE signs 
were assessed in the same room during morning hours at the Meir Medical Center 
ophthalmic outpatient clinic by one of three independent investigators who were masked 
to OSDI scores. The order of testing was (1) TBUT (single measurement per eye after a 
trace of fluorescein was placed in the inferior meniscus off a paper strip), (2) corneal 
staining (the cornea was divided into four areas and staining was graded in each area on 
a scale of 0=none to 3=severe; these four scores were then averaged) and (3) Schrimer’s 
test without anaesthesia (measured at 5 min). Subjects were split into three groups based 
on the presence of DE signs. We opted to group individuals by signs (as opposed to 
symptoms+signs) as the TFI dynamically captures information on the aqueous and lipid 
components of tears. There are many factors that contribute to DE symptoms beyond 
tear components (anatomy, corneal sensitivity, trigeminal pathways beyond the cornea) 
and as such, we would not expect machine assessed parameters to align with DE 
symptoms. 
Controls (no DE signs) were defined by Schrimer >10 mm/5 min, TBUT >7 s and corneal 
staining=0 in both eyes; mild–moderate DE was defined by one or more of the following: 
Schirmer between 2 and 10 mm/5 min, TBUT between 1 and 7 s or corneal staining of 1 
or 2; severe DE was defined by one or more of the following: Schirmer ≤2 mm/5 min, 
TBUT ≤1 s or corneal staining=3. We chose to group individuals based on these three 
DE parameters as they (1) are well-established diagnostic indicators of DE; (2) do not 
require additional instrumentation to capture beyond that routinely available in an eye 
clinic and (3) two of the three parameters (TBUT and Schirmer) have TFI-derived metrics 
which we wished to compare. 
 
 
TFI device based on three-dimension tomography white light interference 
measurement 
TFI measurements were taken 90 min after DE testing to allow sufficient time for 
stabilisation of the ocular surface. A second measurement was taken an average of 45 
min after the first (with a minimum 30 min). The high correlation between the first and 
second TFI measurements reflects that 90 min was a sufficient time for ocular surface 
stabilisation. Based on the reported high correlation between subject eyes and in order 
to reduce the risk for the patients, only one eye from each subject were examined. For 
individuals with DE (mild–moderate or severe DE signs), the more severely affected eye 
was imaged. For controls, the eye with the healthier clinical tear film parameters was 
imaged. This was done as DE signs are highly variable,15 and for this pilot study, we 
wanted to test the ability of the TFI to image a wide range of tear film parameters ranging 
from severely abnormal to normal. The individual performing the imaging was masked to 
the results of clinical testing. 
The imaging process requires that the patient sit in front of the device with his/her head 
positioned on the chin rest. The operator aligned the optics to the corneal centre and 
began recording. The device was manually aligned by a user friendly joystick and data 
was recorded and saved for analysis. Test time was approximately 40 s/eye. The images 
and spectral information were then blindly processed using built in software and several 
output parameters were obtained including: MALT averaged over the measurement 
window, LLT averaged over the measurement window and LBUT time from last blink to 
momentary drop in the LLT level. Of note, this pilot study was performed with a prototype 
device and not all tear film parameters could be calculated from each scan. The 
technology has been subsequently improved and can now derive the major parameters 
from more than 90% of the scans within a couple of minutes. 
STATISTICAL ANALYSIS 
All statistical analyses were performed using SPSS V.22.0 statistical package. 
Frequencies and descriptive statistics were applied to the data, as appropriate. To 
evaluate the new imaging technology, we first examined safety and then focused on 
 
 
reproducibility. Reproducibility was examined via intraclass correlation coefficient (ICC), 
Pearson correlation and Bland-Altman analysis. 
We next evaluated correlations between clinically assessed DE parameters and TFI 
parameters. Specifically, we compared LBUT (TFI parameter) with TBUT (clinical 
parameter) and MALT (TFI parameter) with Schirmer score (clinical parameter) using 
Pearson statistics. We then examined TFI parameters across our clinically determined 
DE groups using analysis of variance methodologies and evaluated the relationship 
between TBUT and LBUT using Bland-Altman analysis. 
Based on receiver operating characteristic analysis, the TFI identified that a MALT value 
of 1700 nm and a LBUT value of 7 s best distinguished between the DE and healthy 
populations. Based on these cut-offs, the machine automatically designated individuals 
to the DE or control group. This machine-generated categorisation was then compared 
with our clinical grouping to calculate a sensitivity and specificity of a DE diagnosis. 
Finally, we re-evaluated our findings considering the effect of age, given demographic 
differences between the groups. 
RESULTS 
STUDY POPULATION 
Forty-nine patients participated in the study. The mean age of all participants was 58.8 
years (SD 15.9). The majority of subjects were female (69%, n=34). Cases with DE were 
older than their counterparts without DE (table 1). 
 
 
 
SAFETY 
No subjects reported discomfort during or after the scanning process. No short-term or 
long-term adverse effects were noted during the study. 
REPRODUCIBILITY 
 
 
The first and second MALT measurements were highly correlated with an ICC of 0.938 
(F=16.116, p<0.001) and a Pearson coefficient (r) of 0.884 (R²=0.781, p<0.001, 
n=39; figure 1). Bland-Altman analysis demonstrates good x-axis distribution and no y-
axis bias indicting good agreement between test and retest, with only 5 of 46 subjects 
exceeding the 2σ threshold (figure 2). 
 
Figure 1 
Scatter plot demonstrating excellent reproducibility in muco-aqueous layer 
measurements with a Pearson coefficient of 0.88. 
 
 
 
Figure 2 
Bland-Altman analysis demonstrating good consistency in muco-aqueous layer 
measurements. 
CORRELATIONS BETWEEN TFI AND CLINICALLY ASSESSED PARAMETERS 
LBUT as measured by the TFI significantly correlated with the clinical measure of TBUT, 
with an ICC of 0.840 (F=6.264, p<0.001) and Pearson coefficient (r) of 0.729 (R²=0.531, 
p<0.001, n=27). Furthermore, based on a paired-samples t-test comparison, no 
significant difference was observed between the two measurements, suggesting that the 
TFI LBUT measurement accurately represents the clinical measure of TBUT (TBUT=6.5 
s; LBUT=5.23 s; p=0.17; n=27). 
Bland-Altman analysis further demonstrates good agreement between LBUT and TBUT. 
The figure 3 demonstrates reasonable x-axis distribution reflecting the study population 
distribution. There is minimal y-axis bias (1 s bias with a SD of 5.5 s), indicating that the 
 
 
LBUT is on average 1 s shorter than the TBUT, and only 2 of 46 data points exceeded 
the 2σ threshold. 
 
Figure 3 
Bland-Altman analysis demonstrating that the lipid break up time closely mirrors the 
clinically assessed tear break up time 
MALT as measured by the TFI significantly correlated with the clinically measured 
Schirmer score, with a Pearson coefficient (r) of 0.306 (R2=0.093, p=0.044) and 0.472 
(R2=0.222, p=0.02) for the first and second MALT measurements, respectively. 
TFI parameters by clinical DE groups 
The MALT was thinner in the DE groups (mild–moderate and severe) compared with the 
control group (table 1). In a similar manner, LBUT as measured by the TFI was 
significantly faster in the DE groups compared with control group. 
 
 
Of note, TFI generated thickness maps of the lipid layer (figure 4) highlight the difficulty 
in using a single central point to quantify lipid layer thickness (LLT). For example, figure 
4A is derived from a control subject. One can appreciate a homogenous but thin lipid layer 
(centre value about 30 nm). In contrast, figure 4B is derived from a subject with DE. One 
can appreciate an uneven map with great differences in LLT ranging between 20 and 120 
nm, with a centre thickness of about 50 nm. 
 
Figure 4 
Sample print outs of the lipid layer thickness maps generated from tear film imager scans. 
Sensitivity and specificity of the TFI compared with clinical grading 
We utilised thresholding methodology for the TFI parameters which resulted in a machine 
categorisation of each subject (DE vs no DE). Both MALT and LBUT parameters were 
used to arrive at this categorisation. We next, compared the machine categorisation to 
the clinically assessed one. The TFI diagnosed DE with 87% sensitivity and 88% 
specificity in comparison to the clinical DE categorisation, as presented in table 2. 
 
 
 
Adjustment for comorbidities 
As expected, age significantly correlated with DE signs (Schirmer r=−0.567, TBUT 
r=−0.539, corneal staining r=0.339). Interestingly, age correlated less closely with the TFI 
parameters of lipid thickness (r=0.027) and MALT (first measurement r=−0.120, second 
measurement r=−0.158) but not surprisingly, correlated with machine generated LBUT 
(r=−0.467). In a linear regression model, age did not remain a significant predictor of 
MALT when considered concomitantly with Schirmer score and of LBUT when considered 
concomitantly with TBUT. 
DISCUSSION 
Our study demonstrates that the TFI is the first imaging modality to reproducibly measure 
muco-aqueous thickness in human subjects. Although the tear film is highly dynamic and 
resets with every blink, reproducibility is the basic requirement from any diagnostic 
method. The average MALT, which is reported by the TFI based on frequent 
measurements and an averaging algorithm, proved to provide a high level of 
reproducibility. This is a remarkable achievement, especially for a highly dynamic system 
like the tear film. No currently available clinical test can capture muco-aqueous thickness, 
which is a core component of DE. Currently available tests that can be used as surrogates 
are the Schirmer’s test which gives information on tear production and the phenol red 
thread which gives information on volume. Neither of these, however, directly measures 
the thickness of the layer on the ocular surface. 
 
 
Encouragingly, controls without DE had a thicker muco-aqueous layer compared with 
individuals with DE. These MALT measurements also correlated well with the clinical 
assessment of Schirmer score. Additionally, LBUT, as measured by the TFI, was found 
to be interchangeable with clinically assessed TBUT and was similarly found to be lower 
in DE versus control subjects. LLT maps further demonstrated the spatial variability in 
lipid layer in individuals with DE versus without DE. Taken together, our results 
demonstrate that the TFI parameters are in strong agreement with traditional diagnostic 
methodologies; yet, the machine offers objective and reproducible tests on new 
parameters that are not able to be assessed clinically or imaged by currently available 
technology. Furthermore, the instrument is easy to use, obtains all values within 40 s and 
does not require patient contact. In fact, high-quality images were successfully obtained 
from all subjects enrolled in this study, and none of the subjects reported discomfort or 
negative effects from imaging. When considering our sensitivity, specificity and predictive 
values, it is important to consider that there is a lack of a gold standard definition for DE, 
and so these values change depending on the specific definition. Given the complexity of 
DE, which has components of aqueous deficiency, lipid deficiency, instability, 
abnormalities in tear components (inflammation, osmolarity), it is not surprising that 
objective tests overall have a low sensitivity. Considering this reality, the TFI numbers are 
better than traditional DE tests that only take into account one component of the tear 
film4 but are still limited by the diagnostic challenged inherent in DE. Similar caution must 
be applied when examining the machine-generated threshold values used to assess 
sensitivity. This study was not powered to determine threshold definitions in DE versus 
control and as such, future studies in expanded populations are needed to evaluate 
appropriate thresholds for differentiating between health and disease. 
The TFI provides several advantages over other clinical and machine-generated DE 
measures. The TFI allows for an unbiased, non-invasive, quick and dynamic assessment 
of the muco-aqueous and lipid layers of the tear film. As such, it is more standardised and 
quicker than the clinical examination and captures information not detected at the slit-
lamp examination (MALT and LLT). Its nanometre resolution is also superior to currently 
available imaging devices. To compare, the LipiView can measure the lipid layer at 
approximately a 30 nm accuracy. HR-OCT has an axial resolution on the order of 2–5 
 
 
μm7 and a measurement rate on the scale of a seconds.8 9 In terms of dynamics, a 
limitation of OCT is that even though the A-scan component can scan thousands of 
images per second, the B-scan component is much slower. Even in a sparse mode, it 
takes the B-scan about 1 s to cover a few 15 μm lines 3 mm in length. This seconds long 
scanning limitation precludes the use of HR-OCT to track tear film dynamics between 
blinks. The Keratograph measures tear meniscus height and non-invasive TBUT but not 
quantify tear component thickness. 
Our encouraging findings need to be considered, given the limitations of this pilot study 
which included a small, defined patient population. Furthermore, while the TFI images the 
central 6 mm of the cornea, which is the area most central to vision, the exclusion of 
peripheral cornea limits the evaluation of tear meniscus parameters and the conjunctival 
regions. Likewise, the TFI does not measure other components of DE, such as osmolarity 
and meibomian gland anatomy. Future studies will need to validate our findings in other 
DE and non-DE age-matched and gender-matched populations and compare our results 
with other DE imaging devices such as the Lipiview. 
Despite these limitations, the TFI is the first machine that can directly and dynamically 
measure the MALT, while simultaneously providing information on lipid layer stability. 
Further studies are needed to address questions regarding the impact of demographics, 
intereye differences, manifestations of DE subgroups (aqueous vs evaporative 
deficiency) and effects of contact lens and surgery on tear film parameters. The utility of 
this instrument for these indications is an important direction of future study. 
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